Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., incorporated on June 22, 1995, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC.
The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications. For hemophilia A, the Company is evaluating SB-525, a gene therapy approach utilizing an adeno-associated virus (AAV) carrying a clotting Factor 8 gene construct driven by its synthetic liver specific promoter. For hemophilia B, it is evaluating, SB-FIX, an in vivo genome editing approach. Its albumin locus ZFN-mediated in vivo genome editing platform has the potential to provide an applicable genetic approach to enzyme replacement for mucopolysaccharidosis (MPS) I. The Food and Drug Association (FDA) granted orphan drug designation to SB-318. Its albumin locus ZFN-mediated in vivo genome editing platform has the potential to provide an applicable genetic approach to enzyme replacement for MPS II. An IND application for the MPS II program, SB-923, has been cleared by the FDA.
The Company has been conducting clinical trials evaluating SB-728-T, a ZFN-modified autologous T-cell product for the treatment of human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS). It also has preclinical programs in hemophilia A and lysosomal storage disorders (LSDs). It also has a preclinical program for huntington's disease (HD) in which it is evaluating a ZFP TF designed to differentially down regulate the mutated disease-causing Huntingtin (HTT) gene. SB-728-HSPC is indicated for the treatment of HIV/AIDS and is in Phase I/II clinical trials.
The Company competes with uniQure, BioMarin, bluebird bio, RegenX, Spark Therapeutics, Dimension Therapeutics, Voyager Therapeutics, Shire, Pfizer, Inc., GlaxoSmithKline, Novartis, Adaptimmune, bluebird bio, Cellectis SA, Juno Therapeutics, Kite Pharma, Lion Biotechnologies, MegaTALs, Precision BioSciences, Inc., Editas Medicine, CRISPR Therapeutics, Caribou BioSciences, Intellia Therapeutics, lnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Sanofi, Regulus Therapeutics, LLC, Merck & Co., Inc., Gilead, Genentech, Inc., Global Blood Therapeutics and Amgen.
501 Canal Blvd
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 1995.| Ticker | SGMO |
| Long Name | Sangamo Therapeutics, Inc. |
| Short Name | Sangamo Therapeutics |